Keybank National Association OH Has $35.27 Million Holdings in ResMed Inc. $RMD

Keybank National Association OH raised its stake in ResMed Inc. (NYSE:RMD) by 46.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 128,831 shares of the medical equipment provider’s stock after buying an additional 40,783 shares during the period. Keybank National Association OH’s holdings in ResMed were worth $35,265,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. SJS Investment Consulting Inc. grew its position in shares of ResMed by 1,433.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 86 shares in the last quarter. WFA of San Diego LLC bought a new stake in shares of ResMed in the second quarter valued at approximately $26,000. GoalVest Advisory LLC acquired a new stake in ResMed during the third quarter worth approximately $37,000. Winnow Wealth LLC bought a new position in ResMed during the 3rd quarter worth $54,000. Finally, Root Financial Partners LLC bought a new position in ResMed during the 3rd quarter worth $64,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Stock Performance

NYSE:RMD opened at $257.76 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.13 and a current ratio of 2.89. ResMed Inc. has a fifty-two week low of $199.92 and a fifty-two week high of $293.81. The company has a 50 day simple moving average of $251.04 and a two-hundred day simple moving average of $263.30. The company has a market capitalization of $37.62 billion, a PE ratio of 25.50, a P/E/G ratio of 1.73 and a beta of 0.88.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $2.81 EPS for the quarter, topping the consensus estimate of $2.68 by $0.13. The company had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.40 billion. ResMed had a net margin of 27.53% and a return on equity of 25.68%. The company’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.43 EPS. Research analysts anticipate that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Thursday, February 12th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Thursday, February 12th. ResMed’s dividend payout ratio (DPR) is currently 24.56%.

Key Stories Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat consensus — GAAP diluted EPS of $2.68 (non‑GAAP $2.81) vs. Street estimates ~ $2.68, revenue $1.423B (+11% YoY), 320 bps gross‑margin improvement and $340M operating cash flow. These metrics support near‑term earnings credibility and cash generation. Read More.
• Positive Sentiment: Board declared a quarterly cash dividend of $0.60 per share (record Feb 12; payable Mar 19), signaling capital return commitment and supporting income investors. Read More.
• Positive Sentiment: Product/innovation catalysts: FDA cleared an AI‑enabled device (“Smart Comfort”) to personalize CPAP settings — strengthens digital/AI positioning and could boost adherence and recurring device/accessory demand. Read More.
• Positive Sentiment: Wells Fargo nudged its price target to $270 (from $265) with an “equal weight” rating — a modest analyst lift that implies limited near‑term upside from that shop. Read More.
• Neutral Sentiment: Analyst landscape remains mixed but generally favorable — several firms maintain outperform/buy views and available median targets sit materially above current price, leaving room for differing investor expectations. Read More.
• Neutral Sentiment: Company hosted the Q2 webcast and transcripts are posted — useful for hearing management’s guide/comments on demand, supply and margin outlook. Read More.
• Negative Sentiment: Expenses rose: SG&A and R&D both increased (~12% YoY) and the company recorded $6M in restructuring charges; higher operating costs could pressure margins if growth slows. Read More.
• Negative Sentiment: Notable insider selling activity was reported in recent months (multiple sales by senior executives), which some investors view as a modest governance/conviction caution. Read More.

Insider Transactions at ResMed

In related news, Director Witte Jan De sold 2,055 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $255.00, for a total value of $524,025.00. Following the completion of the sale, the director directly owned 4,261 shares of the company’s stock, valued at approximately $1,086,555. This represents a 32.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $248.46, for a total transaction of $1,240,063.86. Following the completion of the sale, the chief executive officer directly owned 466,223 shares of the company’s stock, valued at $115,837,766.58. The trade was a 1.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 21,594 shares of company stock valued at $5,403,495 over the last three months. Corporate insiders own 0.65% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on RMD. Stifel Nicolaus raised their target price on shares of ResMed from $260.00 to $265.00 and gave the company a “hold” rating in a report on Friday. Wells Fargo & Company lifted their price objective on shares of ResMed from $265.00 to $270.00 and gave the company an “equal weight” rating in a research note on Friday. Weiss Ratings restated a “hold (c+)” rating on shares of ResMed in a research report on Monday, December 29th. UBS Group reaffirmed a “buy” rating and issued a $345.00 target price on shares of ResMed in a report on Friday, December 12th. Finally, Mizuho decreased their price target on ResMed from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $297.91.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.